NCT00267020 2020-08-31
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 2 Completed
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company